This is a very thorough summary of the TMDX presentation this evening at the conference. They are targeting way more transplants than I expected for the coming years. I am still a holder, after many ups and downs - still one of my larger stock positions.
46 Likes
Attaching a link for another good summary from Matheus - this one from the TD Cowen conference. TMDX also had a pretty good earnings report recently, and the stock is performing well. They are still growing revenue at over 30% YoY the last 2 quarters, working on smaller, more compact devices that will be self monitoring and not require clinical specialist “chaperones” (improved margins), OCS Kidney rolling out late 2026 or early 2027, international expansion ongoing, positive earnings (helped by tax benefit this Q), cash growing, several trials ongoing in 2026 will add volume.
One quote from the summary:
“- CY2026 guidance does not include incremental impact from trials. But it does include 100 patients from lung. On heart, all transplants will be upside to guidance.
- There is significant upside to 2026 guidance if trials go well.”
Strong moat, and growing stronger.
28 Likes